Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015
AMBALALSA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ambalal Sarabhai Enterprises' wholly-owned subsidiary Synbiotics Limited has received USFDA approval for GMP (Good Manufacturing Practice) compliance for the 6th consecutive time without any regulatory actions. Synbiotics manufactures fermentation-based Active Pharmaceutical Ingredients (APIs) and is one of the few producers of Amphotericin B (a critical antifungal drug) in the world. The USFDA inspection was conducted in April 2025 under the API Process Inspection compliance program. The clean approval with zero observations reinforces the facility's strong quality systems and its ability to continue supplying the US market.
Positive for shareholders — the consecutive clean USFDA clearance allows uninterrupted US exports and validates the unit's manufacturing quality, which is a competitive advantage for a niche Amphotericin B producer. May support future revenue from regulated markets.